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ABSTRACT 110 
Scoping reviews, a type of knowledge synthesis, follow a systematic approach to map 111 
evidence on a topic; identify main concepts, theories and sources; and determine where 112 
the gaps are. Though increasing in numbers, the methodological quality and reporting 113 
quality of scoping reviews need improvement. This document presents the Preferred 114 
Reporting Items for Systematic Reviews and Meta-Analyses extension for scoping 115 
reviews (PRISMA-ScR) checklist and explanation.  Developed by a 26-member expert 116 
panel according to published guidance by the EQUATOR (Enhancing the QUAlity and 117 
Transparency Of health Research) Network, the checklist contains 20 essential items 118 
plus 2 optional items. A rationale, along with an example of good reporting, is provided 119 
for each item. The intent of the PRISMA-ScR is to help readers, including researchers, 120 
publishers, commissioners, policy-makers, healthcare providers, guideline developers, 121 
and patients/consumers develop a greater understanding of relevant terminology, core 122 
concepts and key items to report for scoping reviews. 123 
  124 
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1. INTRODUCTION 125 
Scoping reviews can be conducted to meet various objectives.  They may examine the 126 
extent (i.e., size), range (i.e., variety) and nature (i.e., characteristics) of the evidence on 127 
a topic or question; determine the value of undertaking a systematic review; summarize 128 
findings from a body of knowledge that is heterogeneous in terms of methods or 129 
discipline; or identify gaps in the literature to aid planning and commissioning of future 130 
research (1, 2). A recent scoping review by members of our team showed that while the 131 
number of scoping reviews in the literature is increasing steadily, evidence suggests 132 
that both their methodological quality and reporting quality need to improve to facilitate 133 
complete and transparent reporting (1). Results from our survey on scoping review 134 
terminology, definitions and methods revealed a lack of consensus on how to conduct 135 
and report scoping reviews (3).  136 
The Joanna Briggs Institute (JBI) published guidance for the conduct of scoping reviews 137 
in 2015 (4) (which was updated in 2017) (5), based on earlier work by Arksey and 138 
2¶0DOOH\ (6) and Levac et al. (7). However, a reporting guideline for scoping reviews 139 
currently does not exist.  140 
Reporting guidelines outline a minimum set of items to include in research reports and 141 
have been shown to increase methodological transparency and uptake of research 142 
findings (8, 9). Although a reporting guideline exists for systematic reviews, the 143 
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 144 
Statement (10), scoping reviews serve a different purpose than systematic reviews (11). 145 
Systematic reviews are useful for answering clearly defined questions (such as, Does 146 
this intervention improve specified outcomes when compared to a given comparator in 147 
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this population?), whereas scoping reviews are useful for answering much broader 148 
questions (such as, What is the nature of the evidence for this intervention? Or What is 149 
known about this concept?). Given the difference in objectives, and therefore, in the  150 
methodological approach (e.g., presence vs. absence of a risk of bias assessment or 151 
meta-analysis), the reporting items considered to be essential for systematic reviews 152 
would differ for scoping reviews ±  i.e., some PRISMA items may not be appropriate, 153 
while other important considerations may be missing (12-14). We deemed that a 154 
PRISMA extension for scoping reviews is needed to provide reporting guidance for this 155 
specific type of knowledge synthesis. This extension is also intended to be applicable to 156 
evidence maps (15, 16), which share similarities with scoping reviews, and involve a 157 
systematic search of a body of literature to identify knowledge gaps, with a visual 158 
representation of results (e.g., a figure, graph, etc.).  159 
 160 
2. METHODS 161 
The PRISMA extension for scoping reviews (hereafter, the PRISMA-ScR) was 162 
developed according to published guidance by the EQUATOR (Enhancing the QUAlity 163 
and Transparency Of health Research) Network for the development of reporting 164 
guidelines (9). 165 
2.1 Protocol, advisory board and expert panel 166 
Our protocol was drafted by the research team and revised, as necessary, by the 167 
advisory board prior to being listed as a reporting guideline on the EQUATOR (17) and 168 
PRISMA (18) websites. The research team included two leads (ACT, SES) and two 169 
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research coordinators (EL, WZ); all of whom did not participate in the scoring exercises, 170 
and a 4-member advisory board (KOB, HC, DL, DM) with extensive experience with 171 
scoping reviews and/or the development of reporting guidelines. We aimed to have a 172 
representative expert panel in terms of geography and stakeholder type; including 173 
individuals with experience in the conduct, dissemination, or uptake of scoping reviews.  174 
2.2 Survey development and round 1 of Delphi  175 
The initial step to developing the Delphi survey via Qualtrics (an online survey platform) 176 
(19) involved identifying potential modifications to the original 27-item PRISMA 177 
checklist. The modifications were based on a research program carried out by members 178 
of the advisory board to better understand scoping review practices (1, 3, 20) and 179 
included: a broader research question and literature search strategy, optional risk of 180 
bias assessment and consultation exercise (whereby relevant stakeholders contribute to 181 
the work, as GHVFULEHGLQWKH$UNVH\DQG2¶0DOley framework (6)), and the inclusion of a 182 
qualitative analysis. For round 1 of scoring, we prepared a draft of the PRISMA-ScR 183 
(see Supplement 1) and asked expert panel members to rate the extent to which they 184 
agreed with the inclusion of the list of items in using a 7-point Likert scale (1=entirely 185 
disagree, 2=mostly disagree, 3=somewhat disagree, 4=neutral, 5=somewhat agree, 186 
6=mostly agree, 7=entirely agree). Each survey item included an optional text box 187 
where comments about the respective item(s) could be provided. The research team 188 
pilot-tested the survey for content and clarity prior to administering it, and we also sent 189 
bi-weekly reminders to optimize participation.  190 
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2.3 Survey analysis  191 
An 85% consensus rule was selected a priori to signify agreement amongst the expert 192 
panel, to be conservative. This rule required that at a minimum, 85% of the panel mostly 193 
or entirely agreed (i.e. corresponding to the scoring values of 6 or 7 on the Likert scale 194 
used for each of the survey items) with the inclusion of the item in the PRISMA-ScR. If 195 
less than 85% agreement was observed, we considered the item to be discrepant. This 196 
standard was used for all three rounds of scoring to inform the final checklist. For ease 197 
and consistency with how the survey questions were worded, we did not include a 198 
provision for agreement on exclusion (i.e., 85% scoring values of 1 or 2 on the Likert 199 
scale). We summarized all of the submitted comments to help explain the scorings and 200 
identify any issues. For the analysis, the results were stratified by group (i.e., in-person 201 
meeting vs. online, hereafter e-Delphi participants) given the possibility that discrepant 202 
items could differ between the arms.  203 
2.4 In-person arm (round 2 of Delphi)  204 
We established the Chatham House rule (21) at the beginning of the meeting, whereby 205 
participants are free to use information that is shared but may not reveal the identity or 206 
the affiliation of the speaker. Expert panel members were provided the following: their 207 
individual results, the overall group distribution, median and interquartile range and a 208 
summary of the JBI methodological guidance (4), as well as preliminary feedback from 209 
the E-Delphi arm (described below). These data were used to generate and inform the 210 
discussion about each of the discrepant items from round one. ACT and SES facilitated 211 
the discussion using a modified nominal group technique (22), a consensus-building 212 
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method and panel members were subsequently asked to re-score the discrepant items 213 
using sli.do (23), a live audience-response system in a format that resembled the round 214 
one survey. For items that failed to meet the threshold for consensus, working groups 215 
were assembled (described below). The meeting was audio-recorded and transcribed 216 
using Transcribe Me (24), and 3 note-takers independently documented the main 217 
discussion points. The transcript was annotated to complement a master summary of 218 
the discussion points, which was compiled using the 3 note-WDNHUV¶ILOHV 219 
2.5 E-Delphi arm (round 2 of Delphi) 220 
Those who were unable to attend the in-person meeting participated via an online 221 
discussion exercise using Conceptboard (25), a visual collaboration platform that allows 222 
users to provide feedback on µZKLWHERDUGV¶ in real-time. We presented the discrepant 223 
items from round one as a single board in Conceptboard (25) with questions (e.g., ³$fter 224 
reviewing your survey results with respect to this item, please share why you rated this 225 
item the way you did´) assigned to participants as tasks, to facilitate the discussion. E-226 
Delphi panel members were provided with the same materials as those distributed at 227 
the meeting and were encouraged to UHVSRQGWRRWKHUV¶FRPPHQWVDQGLQWHUDFWthrough 228 
a chat feature. The second round of scoring was conducted in Qualtrics using a similar 229 
format as in round one. We shared a summary of the Conceptboard (25) discussion, as 230 
well as the annotated meeting transcript and master summary document so that 231 
participants could learn about the perspectives of the in-person group before re-scoring.  232 
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2.6 Working groups and round 3 of Delphi  233 
To enable panel-wide dialogue and refine the checklist items prior to the final round of 234 
scoring, we created working groups that collaborated by teleconference and email. 235 
Their task was to discuss the discrepant items; in terms of the key issues and 236 
considerations (relating to both concepts and wording) that had been raised in earlier 237 
stages, across both arms. To unite the data from the two arms, we conducted a third 238 
round of scoring using Qualtrics (19). This step involved the full panel scoring an 239 
updated list of items that had failed to reach consensus in the first two rounds across 240 
both arms, with the suggested modifications (relating to both concepts and wording) 241 
from all previous stages incorporated.  242 
2.7 Interactive workshop (testing) 243 
A workshop led by ACT and facilitated by members of the advisory board/expert panel 244 
(SES, CMG, CG, TH, MTM, and MDJP) was held as part of the Global Evidence 245 
Summit in Cape Town, South Africa in September 2017. The PRISMA-ScR was applied 246 
to a scoping review on a health-related topic (26) by participants (e.g., researchers, 247 
scientists, policy makers, managers, and students) to test the checklist .  248 
3. RESULTS 249 
3.1 Expert panel 250 
A total of 37 individuals were invited to participate ± of these, 31 people completed 251 
round 1 and 24 completed all 3 rounds of scoring. Results of the modified Delphi, 252 
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including the number of items that met agreement at each stage are presented in Figure 253 
1. 254 
3.2 Round 1 of Delphi  255 
For the in-person arm, which involved 16 individuals, 9 of the 27 items reached 256 
agreement. For the discrepant items, agreement ranged from 56% for item 15 (risk of 257 
bias) to 81% for items 3 (rationale), 16 (additional analyses), 20 (results of individual 258 
sources) and 23 (additional analyses). For the E-Delphi arm, which involved 15 259 
individuals, 8 of the 27 items met the 85% agreement threshold. For the discrepant 260 
items, agreement ranged from 40% for item 12 (risk of bias) to 80% for items 3 261 
(rationale), 25 (limitations) and 26 (conclusions).  262 
3.3 In-person meeting and round 2 of Delphi  263 
The 16 panel members who attended the in-person meeting in Toronto on November 264 
29th, 2016 were largely from North America, along with others from Australia, Lebanon, 265 
and the United Kingdom. Of the 18 discrepant items from round 1, 11 were re-scored 266 
after discussion. All reached the 85% threshold of agreement, except for one ± item 7, 267 
information sources, which had 83% agreement. For the remaining seven items, the 268 
group felt that notable changes to the items were required, which formed the basis of 269 
action by the working groups.  270 
3.4 E-Delphi online discussion and round 2 Delphi  271 
Fifteen panel members were invited to participate in the online discussion exercise, 272 
from countries including Canada, United Kingdom, Switzerland, Norway, and South 273 
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Africa. Overall, 50% of panelists participated in at least one discussion on 274 
Conceptboard (25) (7/14) and 1 dropped out. Eleven individuals completed the second 275 
scoring exercise of the 19 discrepant items, whereby 5 items reached 85% agreement.  276 
3.5 Working groups and round 3 of Delphi 277 
There were 6 working groups (with one call per group), ranging in size from three to 278 
eight participants, with an average of five people per group. For round 3 of the Delphi, 279 
the 11 items that reached consensus during either round one or round two across both 280 
the in-person and E-Delphi arms were not included. The survey focused on the 281 
remaining 16 items that failed to reach consensus across both arms, to ensure that 282 
decisions made by one arm did not take precedence over the other.  283 
A total of 27 people were invited to participate in round 3 of the Delphi; 16 from the in-284 
person meeting arm and 11 from the E-Delphi arm. Overall, 24 out of 27 completed the 285 
final round of scoring and 3 individuals withdrew (2 from the in-person arm and 1 from 286 
the E-Delphi). Two of the 16 applicable items failed to meet the 85% agreement 287 
threshold; items 10 (data collection process) and 15 (risk of bias across studies). Item 288 
15 was subsequently removed from the checklist, though item 10 was retained but 289 
revised to exclude the optional consultation exercise step described by Arksey and 290 
2¶0DOOH\DQG/HYDFHWDO, which was the source of the disagreement. Furthermore, it 291 
was decided that the consultation exercise could be considered a knowledge translation 292 
activity, which could be conducted for any type of knowledge synthesis.  293 
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3.6 Interactive workshop (testing) 294 
A total of 30 participants attended an interactive workshop at the Global Evidence 295 
Summit in September 2017 in Cape Town, South Africa, where minor revisions were 296 
suggested for wording of the items.   297 
3.7 PRISMA-ScR checklist  298 
The final checklist, with 20 items plus two optional items, is presented in Table 1. It 299 
consists of 10 items that reached agreement in rounds 1 and 2 (1,3,5,6,8,9,17,25-27), 300 
along with the 10 items that were agreed upon in round 3 (2,4, 7,10,11,14,18,20,21,24). 301 
Five items from the original PRISMA were deemed not relevant. They included: items 302 
13 (summary measures, excluded after round 1) and the following 4 items, which were 303 
excluded after round 3: 15 (risk of bias across studies), 16 (additional analyses), 22 (risk 304 
of bias across studies results), and 23 (additional analyses results). See Figure 1 for an 305 
illustration of the process. In addition, because scoping reviews can include many 306 
different types of evidence (e.g., documents, blogs, websites, studies, interviews, 307 
opinions) and are not conducted to examine the risk of bias of the included sources, 308 
items 12 (risk of bias in individual studies) and 19 (risk of bias within studies results) 309 
from the original PRISMA are treated as optional in the PRISMA-ScR.  310 
 311 
3.8 PRISMA-ScR Explanation and Elaboration  312 
Each of the PRISMA-ScR checklist items is elaborated upon in Supplement 2.  In this 313 
document, each item is defined and accompanied by examples of good reporting from 314 
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existing scoping reviews to provide authors with additional guidance on how to use the 315 
PRISMA-ScR. 316 
4. DISCUSSION  317 
The PRISMA-ScR is intended to provide guidance on the reporting of scoping reviews. 318 
To develop this PRISMA extension, we adapted the original PRISMA Statement and 319 
made the following revisions: five items were removed (as they were deemed not 320 
relevant to scoping reviews), two items were deemed optional, and the wording was 321 
modified for all of the items. Our reporting guideline is consistent with the JBI guidance 322 
for scoping reviews, as the JBI guidance is detailed and highlights the importance of 323 
methodological rigor in the conduct of scoping reviews. We hope that the PRISMA-ScR 324 
will improve the reporting of scoping reviews and increase their relevance for decision-325 
making, and that adherence to our reporting guideline will be evaluated in the future, 326 
which will be critical to measure its impact. 327 
 328 
The PRISMA-6F5ZLOOEHKRXVHGRQWKHZHEVLWHVRIWKH(48$7251HWZRUN¶VOLEUDU\of 329 
UHSRUWLQJJXLGHOLQHVDQGWKH.QRZOHGJH7UDQVODWLRQ3URJUDPRI6W0LFKDHO¶V+RVSLWDO330 
(27). To promote its uptake, we will create 1-minute YouTube videos to outline how to 331 
operationalize each of the items; offer webinars for organizations that conduct scoping 332 
reviews, and create 1-page tip sheets for each item. In the future, we will consider 333 
creating an automated email PRISMA-ScR dissemination tool, as well as an online tool 334 
similar to Penelope, which verifies manuscripts for completeness and provides feedback 335 
to authors as they prepare to submit their work to the BMJ Open journal (28). We will 336 
share the PRISMA-ScR widely within our networks, including the Alliance for Health 337 
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Policy and Systems Research, the World Health Organization (WHO) (29) and the 338 
Global Evidence Synthesis Initiative (30). We will also l collect DQGUHYLHZUHDGHUV¶339 
suggestions to improve uptake of the PRISMA-ScR via an online feedback form on the 340 
.QRZOHGJH7UDQVODWLRQ3URJUDPRI6W0LFKDHO¶V+RVSLWDO¶VZHEVLWH (27). 341 
 342 
Study Protocol: Available at EQUATOR and PRISMA websites. 343 
Data Set: Available from corresponding author.  344 
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Table 1: PRISMA-ScR Checklist 419 
 420 
Section Item 
 
PRISMA-ScR checklist item  Reported 
on page # 
Title    
Title 1 Identify the report as a scoping review.   
Abstract    
Structured summary 2 Provide a structured summary including, as applicable: background, objectives, 
eligibility criteria, sources of evidence, charting methods, results and conclusions that 
relate to the review question(s) and objective(s).  
 
Introduction    
Rationale 3 Describe the rationale for the review in the context of what is already known. Explain 
why the review question(s)/objective(s) lend themselves to a scoping review 
approach. 
 
Objectives 4 Provide an explicit statement of the question(s) and objective(s) being addressed with 
reference to their key elements (e.g., population or participants, concepts and 
context), or other relevant key elements used to conceptualize the review question(s) 
and/or objective(s)). 
 
Methods    
Protocol and  
registration 
5 Indicate if a review protocol exists, if and where it can be accessed (e.g., web 
address), and, if available, provide registration information including registration 
number. 
 
Eligibility  
criteria 
6 Specify the characteristics of the sources of evidence (e.g., years considered, 
language, publication status) used as criteria for eligibility, and provide a rationale. 
 
Information  
sources 
7 Describe all information sources (e.g., databases with dates of coverage, contact with 
authors to identify additional sources) in the search, as well as the date the most 
recent search was executed.  
 
Search 8 Present the full electronic search strategy for at least one database, including any 
limits used, such that it could be repeated. 
 
Selection of sources of 9 State the process for selecting sources of evidence (i.e., screening, eligibility) included  
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Section Item 
 
PRISMA-ScR checklist item  Reported 
on page # 
evidence in the scoping review. 
Data  
charting 
process 
10 Describe the methods of charting data from the included sources of evidence (e.g., 
piloted forms; forms that have been tested by the team before their use, whether 
data charting was done independently, in duplicate) and any processes for obtaining 
and confirming data from investigators. 
 
Data items 11 List and define all variables for which data were sought and any assumptions and 
simplifications made.  
 
Critical appraisal of 
individual sources of 
evidence 
12 If done, provide a rationale for conducting a critical appraisal of included sources of 
evidence; describe the methods used and how this information was used in any data 
synthesis (if appropriate). 
 
Summary  
measures 
13 Not applicable for scoping reviews.  
 
Synthesis of  
results 
14 Describe the methods of handling and summarizing the data that were charted.   
 
Risk of bias  
across  
studies 
15 Not applicable for scoping reviews. 
 
Additional analyses 16 Not applicable for scoping reviews.   
Results    
Selection of sources of 
evidence  
17 Give numbers of sources of evidence screened, assessed for eligibility, and included in 
the review, with reasons for exclusions at each stage, ideally using a flow diagram. 
 
Characteristics of 
sources of evidence 
18 For each source of evidence, present characteristics for which data were charted and 
provide the citations. 
 
Critical appraisal 
within sources of 
evidence 
19 If done, present data on critical appraisal of included sources of evidence (see item 
12).  
Results of individual 
sources of evidence 
20 For each included source of evidence, present the relevant data that were charted 
that relate to the review question(s) and objective(s). 
 
Synthesis of  21 Summarize and/or present the charting results as they relate to the review  
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Section Item 
 
PRISMA-ScR checklist item  Reported 
on page # 
results question(s) and objective(s). 
Risk of bias  
across  
studies 
22 Not applicable for scoping reviews. 
 
Additional analyses 23 Not applicable for scoping reviews.  
Discussion    
Summary of  
evidence 
24 Summarize the main results (including an overview of concepts, themes, and types of 
evidence available), explain how they relate to the review question(s) and objectives, 
and consider the relevance to key groups. 
 
Limitations 25 Discuss the limitations of the scoping review process.  
Conclusions 26 Provide a general interpretation of the results with respect to the review question(s) 
and objective(s), as well as potential implications and/or next steps. 
 
Funding    
Funding 27 Describe sources of funding for the included sources of evidence, as well as sources of 
funding for the scoping review. Describe the role of the funders of the scoping review. 
 
 421 
Mini-glossary of PRISMA-ScR terms 
Charting  ? dŚĞƉƌŽĐĞƐƐŽĨĚĂƚĂĞǆƚƌĂĐƚŝŽŶŝŶĂƐĐŽƉŝŶŐƌĞǀŝĞǁŝƐƌĞĨĞƌƌĞĚƚŽĂƐ ?ĚĂƚĂĐŚĂƌƚŝŶŐ ? ?ĂƐƉĞƌƚŚĞƌŬƐĞǇĂŶĚK ?DĂůůĞǇ ? ? ? ? ? ?Ănd Levac et 
al. (2010) frameworks and the JBI guidance (2015, 2017). 
Critical appraisal  ? Refers to the process of systematically examining research evidence to assess its validity, results and relevance before using it 
ƚŽŝŶĨŽƌŵĂĚĞĐŝƐŝŽŶ ?dŚŝƐƚĞƌŵŝŶŽůŽŐǇŝƐƵƐĞĚĨŽƌŝƚĞŵƐ ? ?ĂŶĚ ? ? ?ŝŶƐƚĞĂĚŽĨ ?ƌŝƐŬŽĨďŝĂƐ ? ?ǁŚŝĐŚŝƐŵŽƌĞĂƉƉůŝĐĂďůĞƚŽƐǇstematic reviews of 
interventions) to be inclusive and acknowledge the various sources of evidence that may be included in a scoping review (e.g., quantitative 
and/or qualitative research, expert opinion, policy documents). 
Information sources - This is where sources of evidence (see definition) are compiled from such as, bibliographic databases, social media 
platforms, websites, etc.  
Sources of evidence  ? A more inclusive/ heterogeneous term is used to account for the fact that different types of evidence or data sources (e.g., 
quantitative and/or qualitative research, expert opinion, policy documents) may be eligible in a scoping review, as opposed to only studies.  This 
is not to be confused with information sources (see definition). 
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